RU2010141964A - Модуляторы дофаминовой нейротрансмиссии - Google Patents
Модуляторы дофаминовой нейротрансмиссии Download PDFInfo
- Publication number
- RU2010141964A RU2010141964A RU2010141964/04A RU2010141964A RU2010141964A RU 2010141964 A RU2010141964 A RU 2010141964A RU 2010141964/04 A RU2010141964/04 A RU 2010141964/04A RU 2010141964 A RU2010141964 A RU 2010141964A RU 2010141964 A RU2010141964 A RU 2010141964A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- dihydro
- methylsulfonyl
- benzodioxin
- amine
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 claims abstract 19
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 239000000203 mixture Substances 0.000 claims abstract 19
- 150000003839 salts Chemical class 0.000 claims abstract 19
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 230000010249 dopaminergic function Effects 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004502 levodopa Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NFLCJVNIHXOFPL-VIFPVBQESA-N n-[[(2s)-5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCCC)COC2=C1F NFLCJVNIHXOFPL-VIFPVBQESA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ACSYJWICJIGNLM-UHFFFAOYSA-N 1-(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)-n,n-dimethylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)C)COC2=C1F ACSYJWICJIGNLM-UHFFFAOYSA-N 0.000 claims 1
- CCAIFRVSMWLNEE-UHFFFAOYSA-N 1-(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)-n-methylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC)COC2=C1F CCAIFRVSMWLNEE-UHFFFAOYSA-N 0.000 claims 1
- PEOWPJFIOSDEAU-QMMMGPOBSA-N 1-[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]-n,n-dimethylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(C)C)COC2=C1Cl PEOWPJFIOSDEAU-QMMMGPOBSA-N 0.000 claims 1
- RZUBLNVSYWTUNT-ZETCQYMHSA-N 1-[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]-n-methylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNC)COC2=C1Cl RZUBLNVSYWTUNT-ZETCQYMHSA-N 0.000 claims 1
- CCAIFRVSMWLNEE-ZETCQYMHSA-N 1-[(2s)-5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]-n-methylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNC)COC2=C1F CCAIFRVSMWLNEE-ZETCQYMHSA-N 0.000 claims 1
- NUIPPHWBYVORHW-UHFFFAOYSA-N 1-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]azetidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2OCC1CN1CCC1 NUIPPHWBYVORHW-UHFFFAOYSA-N 0.000 claims 1
- NWDJQBPQRBURCK-UHFFFAOYSA-N 1-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2OCC1CN1CCCC1 NWDJQBPQRBURCK-UHFFFAOYSA-N 0.000 claims 1
- VWZYPYQIYSAIMK-UHFFFAOYSA-N 1-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]azetidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2OCC1CN1CCC1 VWZYPYQIYSAIMK-UHFFFAOYSA-N 0.000 claims 1
- YMYCYPLFBJAPSA-UHFFFAOYSA-N 1-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]piperidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2OCC1CN1CCCCC1 YMYCYPLFBJAPSA-UHFFFAOYSA-N 0.000 claims 1
- MZCVJTWBVVJSPU-UHFFFAOYSA-N 1-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2OCC1CN1CCCC1 MZCVJTWBVVJSPU-UHFFFAOYSA-N 0.000 claims 1
- MDPRCZLYVCMHCH-UHFFFAOYSA-N 1-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]azetidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2CCC1CN1CCC1 MDPRCZLYVCMHCH-UHFFFAOYSA-N 0.000 claims 1
- DRKJABUWGLAFKY-UHFFFAOYSA-N 1-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]piperidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2CCC1CN1CCCCC1 DRKJABUWGLAFKY-UHFFFAOYSA-N 0.000 claims 1
- PQZPJSJBBOGKFA-UHFFFAOYSA-N 1-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2CCC1CN1CCCC1 PQZPJSJBBOGKFA-UHFFFAOYSA-N 0.000 claims 1
- UPPBQQQGJDYDAE-VIFPVBQESA-N 1-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]azetidine Chemical compound C([C@H]1COC2=C(Cl)C=C(C=C2O1)S(=O)(=O)C)N1CCC1 UPPBQQQGJDYDAE-VIFPVBQESA-N 0.000 claims 1
- KMNLDFWCAPNJMO-NSHDSACASA-N 1-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]piperidine Chemical compound C([C@H]1COC2=C(Cl)C=C(C=C2O1)S(=O)(=O)C)N1CCCCC1 KMNLDFWCAPNJMO-NSHDSACASA-N 0.000 claims 1
- JZQRHSKASKRFLH-JTQLQIEISA-N 1-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]pyrrolidine Chemical compound C([C@H]1COC2=C(Cl)C=C(C=C2O1)S(=O)(=O)C)N1CCCC1 JZQRHSKASKRFLH-JTQLQIEISA-N 0.000 claims 1
- YMYCYPLFBJAPSA-GFCCVEGCSA-N 1-[[(3r)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]piperidine Chemical compound C([C@@H]1COC2=CC=C(C=C2O1)S(=O)(=O)C)N1CCCCC1 YMYCYPLFBJAPSA-GFCCVEGCSA-N 0.000 claims 1
- YMYCYPLFBJAPSA-LBPRGKRZSA-N 1-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]piperidine Chemical compound C([C@H]1COC2=CC=C(C=C2O1)S(=O)(=O)C)N1CCCCC1 YMYCYPLFBJAPSA-LBPRGKRZSA-N 0.000 claims 1
- OGXFHSKZILWLNO-NSHDSACASA-N 2,2-dimethyl-n-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC(C)(C)C)COC2=C1 OGXFHSKZILWLNO-NSHDSACASA-N 0.000 claims 1
- CGUICIFMMKFYRR-UHFFFAOYSA-N 2-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]ethanol Chemical compound O1CC(CNCCO)OC2=CC(S(=O)(=O)C)=CC(F)=C21 CGUICIFMMKFYRR-UHFFFAOYSA-N 0.000 claims 1
- AYRSCENJQDTKKW-UHFFFAOYSA-N 2-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methylamino]ethanol Chemical compound O1CC(CNCCO)OC2=CC(S(=O)(=O)C)=CC=C21 AYRSCENJQDTKKW-UHFFFAOYSA-N 0.000 claims 1
- UFXCPZGYIFTGBV-UHFFFAOYSA-N 2-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methylamino]ethanol Chemical compound C1CC(CNCCO)OC2=CC(S(=O)(=O)C)=CC=C21 UFXCPZGYIFTGBV-UHFFFAOYSA-N 0.000 claims 1
- QTSMGAUELLRMTQ-QMMMGPOBSA-N 2-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methylamino]ethanol Chemical compound O1C[C@H](CNCCO)OC2=CC(S(=O)(=O)C)=CC(Cl)=C21 QTSMGAUELLRMTQ-QMMMGPOBSA-N 0.000 claims 1
- PZGIGAYLGVNPAM-UHFFFAOYSA-N 2-methoxy-n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCOC)COC2=C1 PZGIGAYLGVNPAM-UHFFFAOYSA-N 0.000 claims 1
- DTYYIKTYZUMRGL-UHFFFAOYSA-N 2-methoxy-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCOC)CCC2=C1 DTYYIKTYZUMRGL-UHFFFAOYSA-N 0.000 claims 1
- XZLUXENLKSWQTA-UHFFFAOYSA-N 2-methyl-n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC(C)C)COC2=C1 XZLUXENLKSWQTA-UHFFFAOYSA-N 0.000 claims 1
- NJOVSKINYLLZJB-UHFFFAOYSA-N 2-methyl-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC(C)C)CCC2=C1 NJOVSKINYLLZJB-UHFFFAOYSA-N 0.000 claims 1
- XZLUXENLKSWQTA-LLVKDONJSA-N 2-methyl-n-[[(3r)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@H](CNCC(C)C)COC2=C1 XZLUXENLKSWQTA-LLVKDONJSA-N 0.000 claims 1
- XZLUXENLKSWQTA-NSHDSACASA-N 2-methyl-n-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC(C)C)COC2=C1 XZLUXENLKSWQTA-NSHDSACASA-N 0.000 claims 1
- ICGHWPFOUQWXGY-QMMMGPOBSA-N 3,3,3-trifluoro-n-[[(2s)-5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-1-amine Chemical compound O1C[C@H](CNCCC(F)(F)F)OC2=CC(S(=O)(=O)C)=CC(F)=C21 ICGHWPFOUQWXGY-QMMMGPOBSA-N 0.000 claims 1
- YNQIUDXOEYHCHG-VIFPVBQESA-N 3,3,3-trifluoro-n-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound O1C[C@H](CNCCC(F)(F)F)OC2=CC(S(=O)(=O)C)=CC=C21 YNQIUDXOEYHCHG-VIFPVBQESA-N 0.000 claims 1
- HMTHTJXBHPRKIF-ZGTCLIOFSA-N 3-methyl-1-[[(3r)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]piperidine Chemical compound C1C(C)CCCN1C[C@H]1OC2=CC(S(C)(=O)=O)=CC=C2OC1 HMTHTJXBHPRKIF-ZGTCLIOFSA-N 0.000 claims 1
- QIMAGFLOKOCZDJ-UHFFFAOYSA-N 4-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]morpholine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2OCC1CN1CCOCC1 QIMAGFLOKOCZDJ-UHFFFAOYSA-N 0.000 claims 1
- KOFNOWRXIDSMAA-UHFFFAOYSA-N 4-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]morpholine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2OCC1CN1CCOCC1 KOFNOWRXIDSMAA-UHFFFAOYSA-N 0.000 claims 1
- JDCIBHCASSGJOB-UHFFFAOYSA-N 4-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]morpholine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2CCC1CN1CCOCC1 JDCIBHCASSGJOB-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- QVVXSAIFIWLFAB-UHFFFAOYSA-N n,n-dimethyl-1-(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)C)CCC2=C1 QVVXSAIFIWLFAB-UHFFFAOYSA-N 0.000 claims 1
- IWCVJTWXFIQFKV-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-2-methoxyethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCOC)COC2=C1F IWCVJTWXFIQFKV-UHFFFAOYSA-N 0.000 claims 1
- JMVMQHJFSAOHCU-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-2-methylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC(C)C)COC2=C1F JMVMQHJFSAOHCU-UHFFFAOYSA-N 0.000 claims 1
- KRJUEVQPCIMMHI-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-n-methylethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CC)COC2=C1F KRJUEVQPCIMMHI-UHFFFAOYSA-N 0.000 claims 1
- COZAOGJDNDUOHZ-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-n-methylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CCC)COC2=C1F COZAOGJDNDUOHZ-UHFFFAOYSA-N 0.000 claims 1
- HGYAEVSVNVKZRE-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-n-propylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CCC)CCC)COC2=C1F HGYAEVSVNVKZRE-UHFFFAOYSA-N 0.000 claims 1
- IZLXMGUNKCDTRS-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCCC)COC2=C1F IZLXMGUNKCDTRS-UHFFFAOYSA-N 0.000 claims 1
- CYBYLIMSZIVQTB-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC)COC2=C1F CYBYLIMSZIVQTB-UHFFFAOYSA-N 0.000 claims 1
- VPONXHJUNCZNLJ-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]prop-2-en-1-amine Chemical compound O1CC(CNCC=C)OC2=CC(S(=O)(=O)C)=CC(F)=C21 VPONXHJUNCZNLJ-UHFFFAOYSA-N 0.000 claims 1
- SVQXADAXWJUALF-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC(C)C)COC2=C1F SVQXADAXWJUALF-UHFFFAOYSA-N 0.000 claims 1
- WQSMDWKWHVKCSV-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]-n-propylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CCC)CCC)COC2=C1 WQSMDWKWHVKCSV-UHFFFAOYSA-N 0.000 claims 1
- QYNCLOCTEVTRJW-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCCC)COC2=C1 QYNCLOCTEVTRJW-UHFFFAOYSA-N 0.000 claims 1
- XMHPZKPXIAVGLB-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC)COC2=C1 XMHPZKPXIAVGLB-UHFFFAOYSA-N 0.000 claims 1
- KXLHMDZOCIYVOU-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]prop-2-en-1-amine Chemical compound O1CC(CNCC=C)OC2=CC(S(=O)(=O)C)=CC=C21 KXLHMDZOCIYVOU-UHFFFAOYSA-N 0.000 claims 1
- MAMVDUBLWPVXIQ-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCC)COC2=C1 MAMVDUBLWPVXIQ-UHFFFAOYSA-N 0.000 claims 1
- AUAAOFMSOHILNS-UHFFFAOYSA-N n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC(C)C)COC2=C1 AUAAOFMSOHILNS-UHFFFAOYSA-N 0.000 claims 1
- JUKYRQPWRKYMEH-UHFFFAOYSA-N n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCCC)CCC2=C1 JUKYRQPWRKYMEH-UHFFFAOYSA-N 0.000 claims 1
- WIVADSNAUYDWFY-UHFFFAOYSA-N n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC)CCC2=C1 WIVADSNAUYDWFY-UHFFFAOYSA-N 0.000 claims 1
- DPQXIDNQWGFQAA-UHFFFAOYSA-N n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]prop-2-en-1-amine Chemical compound C1CC(CNCC=C)OC2=CC(S(=O)(=O)C)=CC=C21 DPQXIDNQWGFQAA-UHFFFAOYSA-N 0.000 claims 1
- BHNSRSOJVPQCHH-UHFFFAOYSA-N n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC(C)C)CCC2=C1 BHNSRSOJVPQCHH-UHFFFAOYSA-N 0.000 claims 1
- VLRJTIYKLYDRSN-JTQLQIEISA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-2,2-dimethylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC(C)(C)C)COC2=C1Cl VLRJTIYKLYDRSN-JTQLQIEISA-N 0.000 claims 1
- VHIGPNQUCBEFFA-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-2-methoxyethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCCOC)COC2=C1Cl VHIGPNQUCBEFFA-VIFPVBQESA-N 0.000 claims 1
- WVGMRJOHWGRXDB-JTQLQIEISA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-2-methylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC(C)C)COC2=C1Cl WVGMRJOHWGRXDB-JTQLQIEISA-N 0.000 claims 1
- MNWSMMIMVHLCNW-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-3-fluoropropan-1-amine Chemical compound O1C[C@H](CNCCCF)OC2=CC(S(=O)(=O)C)=CC(Cl)=C21 MNWSMMIMVHLCNW-VIFPVBQESA-N 0.000 claims 1
- KYUKFUXUFQAWEO-JTQLQIEISA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-ethylethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(CC)CC)COC2=C1Cl KYUKFUXUFQAWEO-JTQLQIEISA-N 0.000 claims 1
- OSKPEFIPFULJMA-NSHDSACASA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-ethylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(CC)CCC)COC2=C1Cl OSKPEFIPFULJMA-NSHDSACASA-N 0.000 claims 1
- NEYQEXHISQFWSO-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-methylethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(C)CC)COC2=C1Cl NEYQEXHISQFWSO-VIFPVBQESA-N 0.000 claims 1
- ZZZDEINEZALERV-JTQLQIEISA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-methylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(C)CCC)COC2=C1Cl ZZZDEINEZALERV-JTQLQIEISA-N 0.000 claims 1
- DXONWYZCKWNSQB-LBPRGKRZSA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-n-propylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CN(CCC)CCC)COC2=C1Cl DXONWYZCKWNSQB-LBPRGKRZSA-N 0.000 claims 1
- PWLZAFAPSSRHLY-JTQLQIEISA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCCCC)COC2=C1Cl PWLZAFAPSSRHLY-JTQLQIEISA-N 0.000 claims 1
- AJMTVCBEYFDENY-QMMMGPOBSA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC)COC2=C1Cl AJMTVCBEYFDENY-QMMMGPOBSA-N 0.000 claims 1
- QSPLWPQCFSOAHQ-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]prop-2-en-1-amine Chemical compound O1C[C@H](CNCC=C)OC2=CC(S(=O)(=O)C)=CC(Cl)=C21 QSPLWPQCFSOAHQ-VIFPVBQESA-N 0.000 claims 1
- NGWLBYMNHLEBMB-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCCC)COC2=C1Cl NGWLBYMNHLEBMB-VIFPVBQESA-N 0.000 claims 1
- DENNJTQQOMENLP-VIFPVBQESA-N n-[[(2s)-5-chloro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNC(C)C)COC2=C1Cl DENNJTQQOMENLP-VIFPVBQESA-N 0.000 claims 1
- CYBYLIMSZIVQTB-QMMMGPOBSA-N n-[[(2s)-5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC)COC2=C1F CYBYLIMSZIVQTB-QMMMGPOBSA-N 0.000 claims 1
- MAMVDUBLWPVXIQ-SNVBAGLBSA-N n-[[(3r)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@H](CNCCC)COC2=C1 MAMVDUBLWPVXIQ-SNVBAGLBSA-N 0.000 claims 1
- NCEOXFQEEQSDNM-QMMMGPOBSA-N n-[[(3s)-5-fluoro-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C(F)=C2O[C@@H](CNCC)COC2=C1 NCEOXFQEEQSDNM-QMMMGPOBSA-N 0.000 claims 1
- DWDCNTGCXVPWSD-QMMMGPOBSA-N n-[[(3s)-6-(trifluoromethylsulfonyl)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]ethanamine Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C=C2O[C@@H](CNCC)COC2=C1 DWDCNTGCXVPWSD-QMMMGPOBSA-N 0.000 claims 1
- KHWNHRMQYUBIMK-VIFPVBQESA-N n-[[(3s)-6-(trifluoromethylsulfonyl)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C=C2O[C@@H](CNCCC)COC2=C1 KHWNHRMQYUBIMK-VIFPVBQESA-N 0.000 claims 1
- XMHPZKPXIAVGLB-VIFPVBQESA-N n-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCC)COC2=C1 XMHPZKPXIAVGLB-VIFPVBQESA-N 0.000 claims 1
- MAMVDUBLWPVXIQ-JTQLQIEISA-N n-[[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNCCC)COC2=C1 MAMVDUBLWPVXIQ-JTQLQIEISA-N 0.000 claims 1
- JIUTZSUQHJMGKF-UHFFFAOYSA-N n-ethyl-n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CC)COC2=C1F JIUTZSUQHJMGKF-UHFFFAOYSA-N 0.000 claims 1
- KFYTWRPWAHGQKM-UHFFFAOYSA-N n-ethyl-n-[(5-fluoro-7-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CCC)COC2=C1F KFYTWRPWAHGQKM-UHFFFAOYSA-N 0.000 claims 1
- HXMHPIGFBKHTLF-UHFFFAOYSA-N n-ethyl-n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CC)COC2=C1 HXMHPIGFBKHTLF-UHFFFAOYSA-N 0.000 claims 1
- JSKTWSDFQLGSCS-UHFFFAOYSA-N n-ethyl-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CC)CCC2=C1 JSKTWSDFQLGSCS-UHFFFAOYSA-N 0.000 claims 1
- XYKUQSBFOINJJP-UHFFFAOYSA-N n-ethyl-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CCC)CCC2=C1 XYKUQSBFOINJJP-UHFFFAOYSA-N 0.000 claims 1
- WSUXMRJVCYPXQL-UHFFFAOYSA-N n-methyl-1-(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC)COC2=C1 WSUXMRJVCYPXQL-UHFFFAOYSA-N 0.000 claims 1
- MGYNLGKVKLYWQS-UHFFFAOYSA-N n-methyl-1-(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC)CCC2=C1 MGYNLGKVKLYWQS-UHFFFAOYSA-N 0.000 claims 1
- WSUXMRJVCYPXQL-QMMMGPOBSA-N n-methyl-1-[(3s)-6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl]methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2O[C@@H](CNC)COC2=C1 WSUXMRJVCYPXQL-QMMMGPOBSA-N 0.000 claims 1
- XSKZKXSGWYQLOS-UHFFFAOYSA-N n-methyl-n-[(6-methylsulfonyl-2,3-dihydro-1,4-benzodioxin-3-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CCC)COC2=C1 XSKZKXSGWYQLOS-UHFFFAOYSA-N 0.000 claims 1
- DMEIURQIMNPMOQ-UHFFFAOYSA-N n-methyl-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CC)CCC2=C1 DMEIURQIMNPMOQ-UHFFFAOYSA-N 0.000 claims 1
- GTOBKTAKGUERFM-UHFFFAOYSA-N n-methyl-n-[(7-methylsulfonyl-3,4-dihydro-2h-chromen-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CCC)CCC2=C1 GTOBKTAKGUERFM-UHFFFAOYSA-N 0.000 claims 1
- 230000008271 nervous system development Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical compound [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Chemical group 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- 101100533877 Hypocrea jecorina (strain QM6a) sor8 gene Proteins 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 abstract 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical group F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800598 | 2008-04-29 | ||
| DKPA200800598 | 2008-04-29 | ||
| US4905908P | 2008-04-30 | 2008-04-30 | |
| US61/049,059 | 2008-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010141964A true RU2010141964A (ru) | 2012-06-10 |
Family
ID=40940061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141964/04A RU2010141964A (ru) | 2008-04-29 | 2009-04-28 | Модуляторы дофаминовой нейротрансмиссии |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8524766B2 (enExample) |
| EP (1) | EP2271634B1 (enExample) |
| JP (1) | JP5514804B2 (enExample) |
| KR (1) | KR20100135325A (enExample) |
| CN (1) | CN102036976B (enExample) |
| AU (1) | AU2009242092A1 (enExample) |
| BR (1) | BRPI0911772A2 (enExample) |
| CA (1) | CA2722978A1 (enExample) |
| DK (1) | DK2271634T3 (enExample) |
| IL (1) | IL208289A0 (enExample) |
| MX (1) | MX2010011724A (enExample) |
| NZ (1) | NZ588209A (enExample) |
| RU (1) | RU2010141964A (enExample) |
| WO (1) | WO2009133107A1 (enExample) |
| ZA (1) | ZA201006932B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| CN102180856B (zh) * | 2011-03-01 | 2016-01-20 | 浙江华海药业股份有限公司 | 一种制备6-氟-3,4-二氢-2h-1-苯并吡喃-2-甲酸乙酯的方法 |
| JP5876140B2 (ja) | 2011-04-19 | 2016-03-02 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ |
| KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
| JP6481689B2 (ja) | 2014-06-26 | 2019-03-13 | 住友化学株式会社 | フェノール化合物の製造方法 |
| US9125866B1 (en) | 2015-01-28 | 2015-09-08 | King Saud University | Antidepressant compounds |
| CH712810B1 (de) * | 2015-07-21 | 2020-07-15 | Sumitomo Chemical Co | Verfahren zur Herstellung einer 4-(Trifluormethylsulfonyl)phenol-Verbindung. |
| WO2020239568A1 (en) | 2019-05-24 | 2020-12-03 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| WO2024182774A1 (en) * | 2023-03-01 | 2024-09-06 | Alexander Shulgin Research Institute, Inc. | Deuterated and fluorinated empathogens |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3058980A (en) * | 1962-10-16 | Substitution products of benzo- | ||
| US2906757A (en) * | 1959-09-29 | Their preparation | ||
| DE1110175B (de) * | 1957-01-08 | 1961-07-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von Benzodioxanderivaten |
| JPS55124781A (en) * | 1979-03-20 | 1980-09-26 | Shionogi & Co Ltd | 1,4-benzdioxanesulfonamide derivative |
| US5236055A (en) * | 1991-03-13 | 1993-08-17 | Canadian Aging & Rehabilitation Product Development Corporation | Wheel with coaxial drive system mounted in the wheelhub field of the invention |
| US5189171A (en) * | 1991-06-21 | 1993-02-23 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5166367A (en) * | 1991-06-21 | 1992-11-24 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5126366A (en) * | 1991-06-21 | 1992-06-30 | American Home Products Corporation | Aminophenoxyalkyl derivatives of benzodioxan |
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5235055A (en) | 1992-09-02 | 1993-08-10 | American Home Products Corporation | Antipsychotic quinoline derivatives of benzodioxanmethylamine |
| US5245051A (en) * | 1992-09-03 | 1993-09-14 | American Home Products Corporation | Antipsychotic chroman derivatives of benzodioxanmethylamine |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| US5663194A (en) * | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| US5684039A (en) * | 1995-07-25 | 1997-11-04 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| AR004229A1 (es) * | 1995-11-06 | 1998-11-04 | Wyeth Corp | Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| GB0007376D0 (en) | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| JP2005505586A (ja) * | 2001-10-04 | 2005-02-24 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 |
| TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| US20070208166A1 (en) * | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
| NZ550441A (en) * | 2004-05-05 | 2009-07-31 | Hoffmann La Roche | Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both |
| KR101245075B1 (ko) * | 2004-06-08 | 2013-03-18 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진 |
| MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| BRPI0610046A2 (pt) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | derivados de benzodioxano e benzodioxolano e usos destes |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| AR060493A1 (es) * | 2006-04-18 | 2008-06-18 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano. procesos de obtencion. |
| EP2026790A2 (en) * | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Co-therapy for the treatment of epilepsy and related disorders |
| TWI457122B (zh) * | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物 |
| EP2271635A1 (en) | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
-
2009
- 2009-04-28 DK DK09738151.1T patent/DK2271634T3/da active
- 2009-04-28 EP EP09738151.1A patent/EP2271634B1/en not_active Not-in-force
- 2009-04-28 CA CA2722978A patent/CA2722978A1/en not_active Abandoned
- 2009-04-28 BR BRPI0911772A patent/BRPI0911772A2/pt not_active IP Right Cessation
- 2009-04-28 NZ NZ588209A patent/NZ588209A/xx not_active IP Right Cessation
- 2009-04-28 KR KR1020107026636A patent/KR20100135325A/ko not_active Withdrawn
- 2009-04-28 AU AU2009242092A patent/AU2009242092A1/en not_active Abandoned
- 2009-04-28 RU RU2010141964/04A patent/RU2010141964A/ru not_active Application Discontinuation
- 2009-04-28 MX MX2010011724A patent/MX2010011724A/es unknown
- 2009-04-28 US US12/990,048 patent/US8524766B2/en not_active Expired - Fee Related
- 2009-04-28 WO PCT/EP2009/055137 patent/WO2009133107A1/en not_active Ceased
- 2009-04-28 CN CN200980115417XA patent/CN102036976B/zh not_active Expired - Fee Related
- 2009-04-28 JP JP2011506689A patent/JP5514804B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-21 IL IL208289A patent/IL208289A0/en unknown
- 2010-09-29 ZA ZA2010/06932A patent/ZA201006932B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8524766B2 (en) | 2013-09-03 |
| US20110105461A1 (en) | 2011-05-05 |
| MX2010011724A (es) | 2010-11-30 |
| AU2009242092A1 (en) | 2009-11-05 |
| ZA201006932B (en) | 2011-12-28 |
| CN102036976A (zh) | 2011-04-27 |
| EP2271634A1 (en) | 2011-01-12 |
| DK2271634T3 (da) | 2014-05-05 |
| NZ588209A (en) | 2012-08-31 |
| JP2011518858A (ja) | 2011-06-30 |
| BRPI0911772A2 (pt) | 2017-06-27 |
| CN102036976B (zh) | 2013-05-01 |
| EP2271634B1 (en) | 2014-02-12 |
| JP5514804B2 (ja) | 2014-06-04 |
| WO2009133107A1 (en) | 2009-11-05 |
| IL208289A0 (en) | 2010-12-30 |
| KR20100135325A (ko) | 2010-12-24 |
| CA2722978A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010141964A (ru) | Модуляторы дофаминовой нейротрансмиссии | |
| JP2011518858A5 (enExample) | ||
| RU2002119416A (ru) | Новые модуляторы дофаминовой нейротрансмиссии | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| RU2440342C2 (ru) | МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ | |
| TWI224102B (en) | Serotonergic agents | |
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| MX9709211A (es) | Derivados de 2-(1h-4(5)-imidazoil) ciclopropilo. | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2002119417A (ru) | Новые модуляторы дофаминовой нейротрансмиссии | |
| RU2004133068A (ru) | Модуляторы 5нт2с рецептора | |
| PE20081462A1 (es) | Bifenilsulfonilos y fenil heteroaril sufonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
| RU2007139541A (ru) | Производные хромана и хромена и их применение | |
| RU2007106180A (ru) | Производные индола, индазола или индолина | |
| JP2011518859A5 (enExample) | ||
| NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| CA2108967C (en) | Arylmorpholine, preparation and use | |
| JP2014518552A5 (enExample) | ||
| JP2011519839A5 (enExample) | ||
| CA2442423C (en) | Therapeutic drug for psychoneurotic disorders | |
| EA200300915A1 (ru) | Производные изоксазолина в качестве антидепрессантов | |
| DE60329607D1 (de) | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| RU2008102155A (ru) | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP5621087B2 (ja) | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130820 |